[{"address1": "6801 N. Capital of Texas Highway", "address2": "Suite 300 Building 1", "city": "Austin", "state": "TX", "zip": "78731", "country": "United States", "phone": "512 501 2444", "website": "https://www.cassavasciences.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.", "fullTimeEmployees": 29, "companyOfficers": [{"maxAge": 1, "name": "Mr. Remi  Barbier", "age": 63, "title": "Founder, Chairman, President & CEO", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 1114998, "exercisedValue": 297424, "unexercisedValue": 15497283}, {"maxAge": 1, "name": "Mr. Eric J. Schoen", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 426610, "exercisedValue": 0, "unexercisedValue": 1418000}, {"maxAge": 1, "name": "Mr. R. Christopher Cook", "age": 58, "title": "Senior VP, Company Secretary & General Counsel", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 457639, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James W. Kupiec M.D.", "age": 69, "title": "Chief Medical Officer", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": 400000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. George  Thornton Ph.D.", "title": "Senior Vice President of Technology", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Zamloot", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Marsman Pharm.D.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lindsay H. Burns Ph.D.", "title": "Senior Vice President of Neuroscience", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.08, "open": 4.05, "dayLow": 3.96, "dayHigh": 4.4, "regularMarketPreviousClose": 4.08, "regularMarketOpen": 4.05, "regularMarketDayLow": 3.96, "regularMarketDayHigh": 4.4, "beta": -0.419, "volume": 77568, "regularMarketVolume": 77568, "averageVolume": 470900, "averageVolume10days": 116570, "averageDailyVolume10Day": 116570, "bid": 2.0, "ask": 6.51, "bidSize": 1800, "askSize": 2900, "fiftyTwoWeekLow": 3.3, "fiftyTwoWeekHigh": 11.02, "fiftyDayAverage": 6.5313635, "twoHundredDayAverage": 6.5313635, "currency": "USD", "floatShares": 39325000, "netIncomeToCommon": -97217000, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SAVAW", "underlyingSymbol": "SAVAW", "shortName": "Cassava Sciences, Inc.", "longName": "Cassava Sciences, Inc.", "firstTradeDateEpochUtc": 1704724200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "437e3972-eef3-3463-930e-b585e19a181d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.0, "recommendationKey": "none", "totalCash": 121136000, "totalCashPerShare": 2.802, "ebitda": -104427000, "quickRatio": 8.601, "currentRatio": 9.132, "returnOnAssets": -0.34268, "returnOnEquity": -0.53269, "freeCashflow": -51571124, "operatingCashflow": -82025000, "financialCurrency": "USD", "trailingPegRatio": null}]